Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Therapeutics to raise $6.5 million through private placement
Cell Therapeutics (CTI) will sell series D convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of series D convertible preferred stock.
Cell Therapeutics (CTI) will sell series D convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of series D convertible preferred stock.
In experiments performed at the Malmoe University Hospital in Sweden, researchers showed that NOLabs’ technology has a promising ability to kill a wide range of pathogens, including methicillin-resistant
These observations were made based on EKGs from patients who received doses of ARQ 171 from 380 to 760 milligrams per meter squared. QTc prolongation is a disorder
Mr. Kranda led life sciences venture investments as managing director for Vulcan Capital through 2006 and continues to consult for Vulcan. He sits on the board of directors
The notice of compliance with conditions is based on an analysis of clinical trials in which raltegravir, in combination with other antiretroviral agents, was shown to be effective
BioDiem has now received $3 million from a total of up to $8 million in development milestones payable over the next few years and prior to sales of
In a multi-center randomized double blind placebo controlled Phase III study conducted in Japan, 342 obese patients received either KES524 or placebo for 52 weeks. The study demonstrated
Orphan designation will give lenalidomide (Revlimid) access to the centralized procedure for the application for marketing approval, reduce fees associated with applying for marketing approval and protocol assistance
Final analysis of the study data confirmed the findings reported from the preliminary analysis announced October 1, 2007. In the 12-week study, DM-71 had an absolute reduction of
The clinical trial was a randomized, double-blinded, placebo controlled study in healthy volunteers that tested the human monoclonal antibody cocktail against rabies alone, in a dose escalation design,